Header Logo

Connection

IRINA AGOULNIK to Humans

Back to Details
This is a "connection" page, showing publications IRINA AGOULNIK has written about Humans.
IRINA AGOULNIK
Connection Strength
0.195
Humans
  1. Engineering a long acting, non-biased relaxin agonist using Protein-in-Protein technology. Biochem Pharmacol. 2024 09; 227:116401.
    View in: PubMed
    Score: 0.019
  2. Androgen Receptor and Poly(ADP-ribose) Glycohydrolase Inhibition Increases Efficiency of Androgen Ablation in Prostate Cancer Cells. Sci Rep. 2020 03 02; 10(1):3836.
    View in: PubMed
    Score: 0.014
  3. Inositol polyphosphate 4-phosphatase type II regulation of androgen receptor activity. Oncogene. 2019 02; 38(7):1121-1135.
    View in: PubMed
    Score: 0.012
  4. Techniques for Evaluation of AR Transcriptional Output and Recruitment to DNA. Methods Mol Biol. 2018; 1786:219-236.
    View in: PubMed
    Score: 0.012
  5. Nuclear Receptor Corepressor 1 Expression and Output Declines with Prostate Cancer Progression. Clin Cancer Res. 2016 08 01; 22(15):3937-49.
    View in: PubMed
    Score: 0.010
  6. INPP4B suppresses prostate cancer cell invasion. Cell Commun Signal. 2014 Sep 25; 12:61.
    View in: PubMed
    Score: 0.009
  7. Reduced androgen receptor expression accelerates the onset of ERBB2 induced breast tumors in female mice. PLoS One. 2013; 8(4):e60455.
    View in: PubMed
    Score: 0.009
  8. Androgen receptor footprint on the way to prostate cancer progression. World J Urol. 2012 Jun; 30(3):279-85.
    View in: PubMed
    Score: 0.008
  9. INPP4B: the new kid on the PI3K block. Oncotarget. 2011 Apr; 2(4):321-8.
    View in: PubMed
    Score: 0.007
  10. Decreased expression and androgen regulation of the tumor suppressor gene INPP4B in prostate cancer. Cancer Res. 2011 Jan 15; 71(2):572-82.
    View in: PubMed
    Score: 0.007
  11. Coactivator selective regulation of androgen receptor activity. Steroids. 2009 Aug; 74(8):669-74.
    View in: PubMed
    Score: 0.006
  12. Target gene-specific regulation of androgen receptor activity by p42/p44 mitogen-activated protein kinase. Mol Endocrinol. 2008 Nov; 22(11):2420-32.
    View in: PubMed
    Score: 0.006
  13. Androgen receptor coactivators and prostate cancer. Adv Exp Med Biol. 2008; 617:245-55.
    View in: PubMed
    Score: 0.006
  14. Androgens modulate expression of transcription intermediary factor 2, an androgen receptor coactivator whose expression level correlates with early biochemical recurrence in prostate cancer. Cancer Res. 2006 Nov 01; 66(21):10594-602.
    View in: PubMed
    Score: 0.005
  15. Androgen receptor action in hormone-dependent and recurrent prostate cancer. J Cell Biochem. 2006 Oct 01; 99(2):362-72.
    View in: PubMed
    Score: 0.005
  16. Role of SRC-1 in the promotion of prostate cancer cell growth and tumor progression. Cancer Res. 2005 Sep 01; 65(17):7959-67.
    View in: PubMed
    Score: 0.005
  17. A germline variation in the progesterone receptor gene increases transcriptional activity and may modify ovarian cancer risk. J Clin Endocrinol Metab. 2004 Dec; 89(12):6340-7.
    View in: PubMed
    Score: 0.005
  18. Repressors of androgen and progesterone receptor action. J Biol Chem. 2003 Aug 15; 278(33):31136-48.
    View in: PubMed
    Score: 0.004
  19. Discovery of small molecule agonists of the Relaxin Family Peptide Receptor 2. Commun Biol. 2022 11 04; 5(1):1183.
    View in: PubMed
    Score: 0.004
  20. Deletion of inositol polyphosphate 4-phosphatase type-II B affects spermatogenesis in mice. PLoS One. 2020; 15(5):e0233163.
    View in: PubMed
    Score: 0.004
  21. Therapeutic effects of a small molecule agonist of the relaxin receptor ML290 in liver fibrosis. FASEB J. 2019 11; 33(11):12435-12446.
    View in: PubMed
    Score: 0.003
  22. Optimization of the first small-molecule relaxin/insulin-like family peptide receptor (RXFP1) agonists: Activation results in an antifibrotic gene expression profile. Eur J Med Chem. 2018 Aug 05; 156:79-92.
    View in: PubMed
    Score: 0.003
  23. Synthetic non-peptide low molecular weight agonists of the relaxin receptor 1. Br J Pharmacol. 2017 05; 174(10):977-989.
    View in: PubMed
    Score: 0.003
  24. Structural Insights into the Activation of Human Relaxin Family Peptide Receptor 1 by Small-Molecule Agonists. Biochemistry. 2016 Mar 29; 55(12):1772-83.
    View in: PubMed
    Score: 0.003
  25. Identification and optimization of small-molecule agonists of the human relaxin hormone receptor RXFP1. Nat Commun. 2013; 4:1953.
    View in: PubMed
    Score: 0.002
  26. Targeted disruption of the p160 coactivator interface of androgen receptor (AR) selectively inhibits AR activity in both androgen-dependent and castration-resistant AR-expressing prostate cancer cells. Int J Biochem Cell Biol. 2013 Apr; 45(4):763-72.
    View in: PubMed
    Score: 0.002
  27. Identification of small-molecule agonists of human relaxin family receptor 1 (RXFP1) by using a homogenous cell-based cAMP assay. J Biomol Screen. 2013 Jul; 18(6):670-7.
    View in: PubMed
    Score: 0.002
  28. Relaxin signaling in uterine fibroids. Ann N Y Acad Sci. 2009 Apr; 1160:374-8.
    View in: PubMed
    Score: 0.002
  29. Relaxin/RXFP1 signaling in prostate cancer progression. Ann N Y Acad Sci. 2009 Apr; 1160:379-80.
    View in: PubMed
    Score: 0.002
  30. Developmental expression and gene regulation of insulin-like 3 receptor RXFP2 in mouse male reproductive organs. Biol Reprod. 2007 Oct; 77(4):671-80.
    View in: PubMed
    Score: 0.001
  31. Relaxin promotes prostate cancer progression. Clin Cancer Res. 2007 Mar 15; 13(6):1695-702.
    View in: PubMed
    Score: 0.001
  32. Quantifying effects of ligands on androgen receptor nuclear translocation, intranuclear dynamics, and solubility. J Cell Biochem. 2006 Jul 01; 98(4):770-88.
    View in: PubMed
    Score: 0.001
  33. The role of relaxin in endometrial cancer. Cancer Biol Ther. 2006 Jan; 5(1):71-7.
    View in: PubMed
    Score: 0.001
  34. Pim-2 upregulation: biological implications associated with disease progression and perinueral invasion in prostate cancer. Prostate. 2005 Nov 01; 65(3):276-86.
    View in: PubMed
    Score: 0.001
  35. Androgen receptor signaling and vitamin D receptor action in prostate cancer cells. Prostate. 2005 Sep 01; 64(4):362-72.
    View in: PubMed
    Score: 0.001
  36. A novel androgen receptor mutant, A748T, exhibits hormone concentration-dependent defects in nuclear accumulation and activity despite normal hormone-binding affinity. Mol Endocrinol. 2002 Dec; 16(12):2692-705.
    View in: PubMed
    Score: 0.001
  37. Comparison of long-term survival of cytomegalovirus promotre versus Rous Sarcoma virus promoter-driven thymidine kinase gene therapy in nude mice bearing human ovarian cancer. Hybridoma. 1999 Feb; 18(1):93-7.
    View in: PubMed
    Score: 0.001
  38. Adenovirus mediated thymidine kinase gene therapy may enhance sensitivity of ovarian cancer cells to chemotherapeutic agents. Anticancer Res. 1998 Sep-Oct; 18(5A):3421-6.
    View in: PubMed
    Score: 0.001
  39. Telomere length in human white blood cells remains constant with age and is shorter in breast cancer patients. Anticancer Res. 1998 May-Jun; 18(3A):1345-9.
    View in: PubMed
    Score: 0.001
  40. Improvement of gene therapy for ovarian cancer by using acyclovir instead of ganciclovir in adenovirus mediated thymidine kinase gene therapy. Anticancer Res. 1998 Mar-Apr; 18(2A):713-8.
    View in: PubMed
    Score: 0.001
  41. The efficacy of adenovirus-mediated gene therapy of ovarian cancer is enhanced by using the cytomegalovirus promoter. Anticancer Res. 1998 Mar-Apr; 18(2A):719-25.
    View in: PubMed
    Score: 0.001
  42. Human epithelial ovarian cancer xenotransplants into nude mice can be cured by adenovirus-mediated thymidine kinase gene therapy. Anticancer Res. 1997 Mar-Apr; 17(2A):811-3.
    View in: PubMed
    Score: 0.001
  43. In vivo gene therapy of ovarian cancer by adenovirus-mediated thymidine kinase gene transduction and ganciclovir administration. Gynecol Oncol. 1996 May; 61(2):175-9.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.